Piermont Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Piermont Capital Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-52,195	Closed	-$481K	–	280
2017 Q1	$481K	Buy	+52,195	New	+$458K	0.11%	234
2016 Q2	–	Sell	-21,895	Closed	-$221K	–	315
2016 Q1	$221K	Buy	21,895 +835	+4%	+$9.8K	0.07%	227
2015 Q4	$475K	Sell	21,060 -1,440	-6%	-$29.5K	0.15%	150
2015 Q3	$373K	Hold	22,500	–	–	0.12%	180
2015 Q2	$506K	Buy	+22,500	New	+$555K	0.15%	165

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Piermont Capital Management's OMED Position: Q2 2017 in Review

Piermont Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 52,195 shares — an estimated $481K sold.

Piermont Capital Management first reported a position in OMED in Q2 2015 and held it in 5 quarters. The position peaked at $506K in Q2 2015. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

Piermont Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Piermont Capital Management sold 52,195 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $481K.
Piermont Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2015 and held it in 5 quarters.
Piermont Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $506K in Q2 2015.
68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on Piermont Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.